Literature DB >> 26125598

DNA Aptamer Assembly as a Vascular Endothelial Growth Factor Receptor Agonist.

Vidhya Ramaswamy1, Adam Monsalve1, Larysa Sautina2, Mark S Segal2,3, Jon Dobson1,4,5, Josephine B Allen1,5.   

Abstract

Controlling receptor-mediated processes in cells is paramount in many research areas. The activity of small molecules and growth factors is difficult to control and can lead to off-target effects through the activation of nonspecific receptors as well as binding affinity to nonspecific cell types. In this study, we report the development of a molecular trigger in the form of a divalent nucleic acid aptamer assembly toward vascular endothelial growth factor receptor-2 (VEGFR2). The assembly binds to VEGFR2 and functions as a receptor agonist with targeted receptor binding, promoting receptor phosphorylation, activation of the downstream Akt pathway, upregulation of endothelial nitric oxide synthase, and endothelial cell capillary tube formation. The agonist action we report makes this aptamer construct a promising strategy to control VEGFR2-mediated cell signaling.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26125598      PMCID: PMC4576944          DOI: 10.1089/nat.2014.0519

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  28 in total

1.  Developing aptamers into therapeutics.

Authors:  R R White; B A Sullenger; C P Rusconi
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

2.  Influencing receptor-ligand binding mechanisms with multivalent ligand architecture.

Authors:  Jason E Gestwicki; Christopher W Cairo; Laura E Strong; Karolyn A Oetjen; Laura L Kiessling
Journal:  J Am Chem Soc       Date:  2002-12-18       Impact factor: 15.419

3.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.

Authors:  C Tuerk; L Gold
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

4.  In vitro selection of RNA molecules that bind specific ligands.

Authors:  A D Ellington; J W Szostak
Journal:  Nature       Date:  1990-08-30       Impact factor: 49.962

Review 5.  Signal transduction by receptors with tyrosine kinase activity.

Authors:  A Ullrich; J Schlessinger
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

6.  High affinity ligands from in vitro selection: complex targets.

Authors:  K N Morris; K B Jensen; C M Julin; M Weil; L Gold
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

7.  A new antithrombogenic material with long polyethyleneoxide chains.

Authors:  Y Mori; S Nagaoka; H Takiuchi; T Kikuchi; N Noguchi; H Tanzawa; Y Noishiki
Journal:  Trans Am Soc Artif Intern Organs       Date:  1982

Review 8.  The biology of VEGF and its receptors.

Authors:  Napoleone Ferrara; Hans-Peter Gerber; Jennifer LeCouter
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

9.  2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain.

Authors:  J Ruckman; L S Green; J Beeson; S Waugh; W L Gillette; D D Henninger; L Claesson-Welsh; N Janjić
Journal:  J Biol Chem       Date:  1998-08-07       Impact factor: 5.157

10.  Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2.

Authors:  Rebekah R White; Siqing Shan; Christopher P Rusconi; Geetha Shetty; Mark W Dewhirst; Christopher D Kontos; Bruce A Sullenger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-11       Impact factor: 11.205

View more
  12 in total

1.  MechanoBioTester: A Decoupled Multistimulus Cell Culture Device for Studying Complex Microenvironments In Vitro.

Authors:  Bryan D James; Nicolas Montoya; Josephine Allen
Journal:  ACS Biomater Sci Eng       Date:  2020-05-08

Review 2.  Advances in the development of aptamer drug conjugates for targeted drug delivery.

Authors:  Ke Chen; Bo Liu; Bo Yu; Wen Zhong; Yi Lu; Jiani Zhang; Jie Liao; Jun Liu; Ying Pu; Liping Qiu; Liqin Zhang; Huixia Liu; Weihong Tan
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-10-31

Review 3.  Aptamers as targeted therapeutics: current potential and challenges.

Authors:  Jiehua Zhou; John Rossi
Journal:  Nat Rev Drug Discov       Date:  2016-11-03       Impact factor: 84.694

4.  Altered stoichiometry of an evolved RNA aptamer.

Authors:  Shoji Ohuchi; Beatrix Suess
Journal:  RNA       Date:  2017-12-28       Impact factor: 4.942

5.  Binding and Structural Properties of DNA Aptamers with VEGF-A-Mimic Activity.

Authors:  Toru Yoshitomi; Misako Hayashi; Takumi Oguro; Keiko Kimura; Fumiya Wayama; Hitoshi Furusho; Keitaro Yoshimoto
Journal:  Mol Ther Nucleic Acids       Date:  2020-01-14       Impact factor: 8.886

6.  A chemically unmodified agonistic DNA with growth factor functionality for in vivo therapeutic application.

Authors:  Ryosuke Ueki; Satoshi Uchida; Naoto Kanda; Naoki Yamada; Ayaka Ueki; Momoko Akiyama; Kazuko Toh; Horacio Cabral; Shinsuke Sando
Journal:  Sci Adv       Date:  2020-04-01       Impact factor: 14.136

7.  A hotspot for enhancing insulin receptor activation revealed by a conformation-specific allosteric aptamer.

Authors:  Na-Oh Yunn; Mangeun Park; Seongeun Park; Jimin Lee; Jeongeun Noh; Euisu Shin; Sung Ho Ryu
Journal:  Nucleic Acids Res       Date:  2021-01-25       Impact factor: 16.971

Review 8.  Recent Progress and Opportunities for Nucleic Acid Aptamers.

Authors:  Jonghoe Byun
Journal:  Life (Basel)       Date:  2021-02-28

9.  Anti-VEGF-R2 Aptamer and RGD Peptide Synergize in a Bifunctional Hydrogel for Enhanced Angiogenic Potential.

Authors:  Tanaya Roy; Bryan D James; Josephine B Allen
Journal:  Macromol Biosci       Date:  2020-11-16       Impact factor: 4.979

Review 10.  Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics.

Authors:  Domenica Musumeci; Chiara Platella; Claudia Riccardi; Federica Moccia; Daniela Montesarchio
Journal:  Cancers (Basel)       Date:  2017-12-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.